Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 30,763 articles published since 2009
|||| 30,763 

These are the 45 published retractions about Pancreatic Neoplasms that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2
1 Retraction Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy. 2018

Zhang, Yu / Zhu, Xiaofei / Liu, Denghui / Song, Jiaqi / Zhang, Huojun / Lu, Jianping. ·Department of Radiology, Changhai Hospital Affiliated to the Second Military Medical University, Changhai Road 168, Yangpu district, Shanghai, 200433, People's Republic of China. · Department of Oncology Radiation, Changhai Hospital Affiliated to the Second Military Medical University, Changhai Road 168, Yangpu district, Shanghai, 200433, People's Republic of China. · Department of Orthopedics, No. 113 Hospital of People's Liberation Army, East Zhongshan Road 377, Jiangdong District, Ningbo, 315000, People's Republic of China. · Department of health statistics, Second Military Medical University, Xiangyin Road 800, Yangpu district, Shanghai, 200433, People's Republic of China. · Department of Radiology, Changhai Hospital Affiliated to the Second Military Medical University, Changhai Road 168, Yangpu district, Shanghai, 200433, People's Republic of China. LDH870118@163.com. ·Cancer Imaging · Pubmed #29471875.

ABSTRACT: BACKGROUND: To identify the value of the pre-treatment apparent diffusion coefficient (ADC) derived from diffusion weighted imaging (DWI) in predicting the overall survival (OS) for locally advanced pancreatic cancer (LAPC) treated with Cyberknife followed by sequential S-1 chemotherapy. METHODS: Patients with UICC-T4 LAPC who underwent DWI scan (3.0 Tesla) using two b-values (0, 600 s/mm RESULTS: A total of 41 patients (28 males and 13 females) were included, with a median age of 64 years, with 5 patients (3 males and 2 females) lost. The median OS was 11.7 months (range 2.8-23.3) among all 41 patients. The 1-year OS was 46% (95% CI 30%-62%). Univariate and multivariate analyses indicated that pre-treatment ADC value (HR 10.652, P = 0.0093), age (HR 0.952, P = 0.015), CA19-9 (HR 1.001, P = 0.0022) and administration of S-1 (HR 0.128, P = 0.0002) were independent predicting factors of OS. CONCLUSION: The mean ADC value of the primary tumor on pre-treatment DWI imaging was an independent predictor of OS in patients with LAPC receiving Cyberknife followed by sequential S-1.

2 Retraction Pancreatic neuroendocrine tumors. Prognostic factors. 2017

A Cienfuegos, Javier / Rotellar, Fernando / Ruiz-Canela, Miguel. ·Cirugía/ Apoyo Investigación, Clínica Universidad de Navarra, España. · Cirugía General y Digestiva, Clínica Universidad de Navarra, España. · Department of Preventive Medicine and Public Healt, Medical School. University of Navarra, España. ·Rev Esp Enferm Dig · Pubmed #28929779.

ABSTRACT: We thank Modesto Varas et al. for their opportune comments with regard to the oncologic outcomes of our series of patients undergoing surgery for pancreatic neuroendocrine tumors (PNET). We agree with Varas et al. in relation to the increase in non-functional tumors (73%) and the incidental form of presentation (44%). These figures are in line with those presented in most series.

3 Retraction SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells. 2017

Li, Yonghe / Oliver, Patsy G / Lu, Wenyan / Pathak, Vibha / Sridharan, Sivaram / Augelli-Szafran, Corinne E / Buchsbaum, Donald J / Suto, Mark J. ·Drug Discovery Division, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35255, USA. Electronic address: yli@southernresearch.org. · Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA. · Drug Discovery Division, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35255, USA. ·Cancer Lett · Pubmed #28043913.

ABSTRACT: Activation of Wnt/β-catenin signaling is associated with pancreatic and colorectal cancer, among others. To-date, there are no FDA-approved small molecule Wnt/β-catenin inhibitors and many past efforts resulted in compounds with undesirable off-target effects. We recently identified a series of benzimidazole analogs as potent inhibitors of Wnt/β-catenin signaling. Here, we show that the lead compound SRI36160 displayed selective Wnt inhibition and potent antiproliferative activity in pancreatic and colorectal cancer cells. Moreover, SRI36160 had no effect on STAT3 and mTORC1 signaling in pancreatic and colorectal cancer cells, and was not effective in inhibiting proliferation of non-cancerous cells. Our findings suggest that this series of benzimidazole analogs presents a novel approach for the treatment of Wnt-dependent cancers such as colorectal and pancreatic cancer.

4 Retraction The clinical utility of image-guided iodine-125 seed in patients with unresectable pancreatic cancer. 2016

Niu, Hongxin / Zhang, Xikun / Wang, Bin / Zhou, Zhao / Wang, Jian / Xu, Zhongfa. ·Department of Minimally Invasive Surgery, Affiliated Hospital of Shandong Academy of Medical Sciences, 38# Wuyingshan Road, Jinan, 250031, China. · Department of Minimally Invasive Surgery, Affiliated Hospital of Shandong Academy of Medical Sciences, 38# Wuyingshan Road, Jinan, 250031, China. xuzfshandong@163.com. ·Tumour Biol · Pubmed #26353858.

ABSTRACT: In the present study, we investigated the clinical effects of image-guided iodine-125 ((125)I) seed on unresectable pancreatic cancer. Twenty-five patients with unresectable pancreatic cancer were enrolled in this study, including 13 patients with seed implantation and 12 patients as control. The survival status, clinical benefits, objective curative effects, and relevant tumor markers were analyzed to assess the feasibility and safety of interstitial (125)I seed implantation. We found that the clinical benefit rate of the seed implantation group is 92.3 % (12/13), compared with 41.7 % (5/12) in the control, and the difference was statistically significant (p < 0.01). Compared with control, patients with seed implantation had significantly shorter operative time, less bleeding, higher albumin, shorter periods to bowel movement, and normal diet as well as lower risk of complications (p < 0.001). The differences of objective curative effects adverse effects, complications, and median survival between these two groups were not significant statistically (p > 0.05). In conclusion, (125)I seed implantation provides a safe and effective method to inhibit the tumor development, relieve pain, and improve quality of life for unresectable pancreatic cancer. These findings need to be validated by conducting further studies with larger cohorts.

5 Retraction MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer. 2015

Li, Q W / Zhou, T / Wang, F / Jiang, M / Liu, C B / Zhang, K R / Zhou, Q / Tian, Z / Hu, K W. ·Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China. ·Genet Mol Res · Pubmed #26662405.

ABSTRACT: It has been shown that microRNA-215 (miR-215) is dysregulated in several human malignancies, and this correlates with tumor progression. However, its expression and function in pancreatic cancer is still unclear. The aim of this study was to explore the effects of miR-215 on pancreatic cancer formation and progression. Using quantitative RT-PCR, we detected miR-215 expression in pancreatic cancer cell lines and primary tumor tissues. The association of miR-215 expression with clinicopathological factors and prognosis was also analyzed. We then observed the effects of miR-215 on the biological behavior of pancreatic cancer cells. Lastly, the potential regulatory function of miR-215 on ZEB2 expression was investigated. miR-215 expression levels were significantly downregulated in pancreatic cancer samples and cell lines. Decreased miR-215 expression was significantly associated with large tumor size, advanced TNM stage, lymph node metastasis, vessel invasion, and lower overall survival. Multivariate regression analysis corroborated that downregulation of miR-215 was an independent unfavorable prognostic factor. Overexpression of miR-215 inhibited pancreatic cancer cell proliferation, invasion, and migration; promoted cell apoptosis in vitro; and suppressed tumorigenicity in vivo. Further, ZEB2 was confirmed as a direct target of miR-215 by using a luciferase reporter assay. These findings indicate that miR-215 may act as a tumor suppressor in pancreatic cancer cells, and could serve as a novel therapeutic target for miR-based therapy.

6 Retraction High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). 2015

Gong, Chen / Zhang, Yixin / Chen, Yinji / Zhang, Haifeng / Liu, Xiaorong / Xue, Huaqing / Ji, Li / Wang, Liang / Yang, Linlin / Zhou, Guoxiong / Wan, Chunhua. ·Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China. · Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu Province, China. · Department of General Surgery, Nantong University Cancer Hospital, Nantong, 226001, Jiangsu Province, China. · National Engineering Lab of Food Storage and Transportation, Nanjing University of Finance and Economics, Nanjing, 210023, Jiangsu Province, China. · Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China. zhougx@ntu.edu.cn. · Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu Province, China. Chwan@ntu.edu.cn. ·Tumour Biol · Pubmed #26088450.

ABSTRACT: Recent studies have identified that ErbB3 binding protein 1 (EBP1) is broadly expressed in various cancer tissues and critically involved in plenty of biological processes in this regard. However, the functional role of EBP1 in pancreatic ductal adenocarcinoma (PDAC) has never been elucidated. In this study, we found that EBP1 could serve as a prognostic biomarker of PDAC. Western blot analysis revealed that EBP1 was remarkably upregulated in PDAC tissues and cell lines. Using immunohistochemical analysis, we showed that the expression of EBP1 was correlated with tumor size (P = 0.004), histological differentiation (P = 0.041), and tumor node metastasis (TNM) stage (P = 0.000). Notably, Kaplan-Meier curve showed that high expression of EBP1 predicted significantly worsened prognosis of PDAC patients (P = 0.001). In addition, knockdown of EBP1 expression suppressed PDAC cell proliferation and retarded cell cycle progression. Furthermore, depletion of EBP1 induced the apoptosis of Panc-1 cells. Of great interest, we found that EBP1 interacted with anti-apoptotic protein, Bcl-xL, and promoted its accumulation. In summary, our results suggest that EBP1 is a novel prognostic indicator and potential therapeutic target of PDAC, shedding new insights into the important role of EBP1 in cancer development.

7 Retraction Transforming growth factor β receptor signaling restrains growth of pancreatic carcinoma cells. 2015

Zhao, Zhiming / Xi, Hao / Xu, Dabin / Li, Chenggang. ·Department of Surgical Oncology, Chinese PLA General Hospital, Beijing, 100853, China. zhiming_zhao@163.com. · Department of Surgical Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. zhiming_zhao@163.com. · Department of Hepatobiliary Surgery, The Hospital of Shunyi District, Beijing, 101300, China. · Department of Surgical Oncology, Chinese PLA General Hospital, Beijing, 100853, China. ·Tumour Biol · Pubmed #25934336.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is extremely malignant. Efficient control of cancer growth may substantially improve the survival of PDAC patients. However, no efficient treatments are so far available. Here, we inhibited transforming growth factor β (TGFβ) receptor signaling by overexpression of a key inhibitor of this pathway, SMAD7, in the mouse pancreas, using a recently developed intraductal infusion method. Overexpression of SMAD7 significantly increased growth of both implanted PDAC and PDAC by K-ras modification. Our data thus suggest that TGFβ receptor signaling restrains growth of PDAC, and modulation of TGFβ receptor signaling may be an effective treatment for PDAC.

8 Retraction miR-663 attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic cancer. 2015

Zang, Wenqiao / Wang, Yuanyuan / Wang, Tao / Du, Yuwen / Chen, Xiaonan / Li, Min / Zhao, Guoqiang. ·College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan Province, China. zangwenqiao@sina.com. · College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan Province, China. 50998719@qq.com. · Department of Hemato-tumor, The First Affiliated Hospital of Henan University of TCM, Zhengzhou, 450000, China. wang0371@126.com. · College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan Province, China. yuwen0107@126.com. · College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan Province, China. chenxiaonan09@126.com. · College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan Province, China. limin75@163.com. · College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan Province, China. zhaogq@zzu.edu.cn. ·Mol Cancer · Pubmed #25744894.

ABSTRACT: BACKGROUND: miR-663 is associated with many important biologic processes, such as the evolution, development, viral infection, inflammatory response, and carcinogenesis among vertebrates. However, the molecular function and mechanism of miR-663 in pancreatic cancer growth and invasion is still unclear. METHODS: Western blot and real-time PCR were used to study the expression level of eEF1A2 protein and miR-663 in pancreatic cancer tissues and cell lines. The Pearson χ (2) test was used to determine the correlation between miR-663 expression and clinicopathologic features of patients. Patients' survival was analyzed using the Kaplan-Meier method, using the log-rank test for comparison. The biological function of miR-663 was examined by measuring cell growth, cell invasion and apoptosis analysis in vitro and in vivo. miR-663 target gene and signaling pathway was identified by luciferase activity assay and western blot. RESULTS: We found that, in pancreatic cancer, eEF1A2 was significantly upregulated but miR-663 was significantly downregulated. Further results showed that the expression level of eEF1A2 and miR-663 was strongly associated with TNM stage and node metastasis status of the patients. miR-663 and eEF1A2 were inversely correlated with each other, and the changes in the expression levels of each can also predict the survival of patients with pancreatic cancer. We identified miR-663 as a tumor attenuate molecular that attenuated the proliferation and invasion of pancreatic cancer cells both in vitro and in vivo. Finally, we confirmed that the expression of eEF1A2 can partially restore the pro-apoptotic and anti-invasion functions of miR-663. CONCLUSIONS: miR-663 attenuated the proliferation and invasion of pancreatic cells both in vitro and in vivo by directly targeting eEF1A2. miR-663 and eEF1A2 might be potential targets for the treatment of pancreatic cancer in the future.

9 Retraction Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured? 2015

Chen, Tao / Zhang, Min-Gui / Yu, Xian-Jun / Liu, Liang. ·Department of Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, China E-mail : zhejiangchentao@163.com. ·Asian Pac J Cancer Prev · Pubmed #25684504.

ABSTRACT: BACKGROUND: Postoperative carbohydrate antigen 19-9 (CA19-9) is an independent predictor of survival for pancreatic ductal adenocarcinoma (PDAC), and more powerful than preoperative CA19-9. However, making decisions just dependent on postoperative CA19-9 may result in necessary treatments not being performed. MATERIALS AND METHODS: A total of 178 patients with resected PDAC were eligible for this retrospective study, classified into two corresponding subgroups according to postoperative CA19-9. Prognostic significance of all clinicopathologic factors was evaluated by univariate and multivariate analyses. RESULTS: Postoperative CA19-9, preoperative CA125 and lymph node status were independent predictors. Better predictive performances for overall survival (OS) and recurrence-free survival (RFS) were achieved by postoperative CA19-9 compared to preoperative CA125 and lymph node status. Particularly, preoperative CA125 was associated with poor OS (p<0.001 for the normalized CA19-9 patients, p=0.012 for the elevated) and RFS (p=0.005 for the normalized, p=0.004 for the elevated). Moreover, preoperative CA125 levels related with survival in double- negative patients. CONCLUSIONS: Normalization of CA19-9 is not tantamount to be cured. Preoperative CA125 is a critical predictor for PDAC patients, especially in double-negative patients.

10 Retraction Augmented TGFβ receptor signaling induces apoptosis of pancreatic carcinoma cells. 2015

Li, Chenggang / Zhao, Zhiming / Zhou, Zhipeng / Liu, Rong. ·Department of Surgical Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China, chenggang_li14@163.com. ·Tumour Biol · Pubmed #25476855.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant tumor in humans. Thus, understanding the tumorigenesis of PDAC appears to help develop efficient therapy. Here, we show that activated TGFβ receptor signaling induces apoptosis of pancreatic carcinoma cells in vitro and in vivo, suggesting that activation of TGFβ receptor signaling may prevent development of PDAC.

11 Retraction A comprehensive analysis of candidate genes and pathways in pancreatic cancer. 2015

Liu, Jie / Li, Jun / Li, Hali / Li, Aidong / Liu, Biou / Han, Liou. ·Department of general surgery, The First Affiliated Hospital of Harbin Medical University, No.23, Youzheng Street, Nangang District, Harbin, 150001, China. ·Tumour Biol · Pubmed #25409614.

ABSTRACT: The study aimed to dissect the molecular mechanism of pancreatic cancer by a range of bioinformatics approaches. Three microarray datasets (GSE32676, GSE21654, and GSE14245) were downloaded from Gene Expression Omnibus database. Differentially expressed genes (DEGs) with logarithm of fold change (|logFC|) >0.585 and p value <0.05 were identified between pancreatic cancer samples and normal controls. Transcription factors (TFs) were selected from the DEGs based on TRASFAC database. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed for the DEGs using The Database for Annotation, Visualization and Integrated Discovery (p value <0.05), followed by construction of protein-protein interaction (PPI) network using Search Tool for the Retrieval of Interacting Genes software. Latent pathway identification analysis was applied to analyze the DEGs-related pathways crosstalk and the pathways with high weight value were included in the pathway crosstalk network using Cytoscape. Sixty-five DEGs were screened out. CCAAT/enhancer-binding protein delta (CEBPD), FBJ osteosarcoma oncogene B (FOSB), Stratifin (SFN), Krüppel-like factor 5 (KLF5), Pentraxin 3 (PTX3), and nuclear receptor subfamily 4, group A, member 3 (NR4A3) were important TFs. Interleukin-6 (IL-6) was the hub node of the PPI network. DEGs were significantly enriched in NOD-like receptor signaling pathway which was primarily interacted with inflammation and immune related pathways (cytosolic DNA-sensing, hematopoietic cell lineage, intestinal immune network for IgA production and chemokine pathways). The study suggested CEBPD, FOSB, SFN, KLF5, PTX3, NR4A3, IL-6, and NOD-like receptor pathways were involved in pancreatic cancer.

12 Retraction Sports-induced blood sugar utilization prevents development of pancreatic ductal adenocarcinoma. 2015

Lu, Jinkui / Yin, Xiaojian / Jiang, Jiazhen. ·Key Laboratory of Adolescent Health Assessment and Exercise Intervention, Ministry of Education, School of Physical Education and Health, East China Normal University, 500 Dongchuan Rd, Shanghai, 200241, China, jinkui_lu@163.com. ·Tumour Biol · Pubmed #25283383.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor of extremely high lethality in humans. Pancreatic intraepithelial neoplasia (PanIN) is the predominant precancerous lesion for PDAC and is frequently detected in the normal and inflamed pancreas. However, only a few of PanIN eventually progress into PDAC. Thus, understanding of the regulation of PanIN-to-PDAC conversion appears to be critical for prevention of the occurrence of PDAC. Here, we evaluated the effect of sports on the progression of PanIN into PDAC in an established mouse PDAC model (Ptf1a-Cre; K-ras fx/fx). We found that swimming (3 min twice per day) since 12 weeks of age significantly decreased the incidence of the development of PDAC in these PanIN-baring mice at 24 weeks of age. Moreover, swimming significantly decreased fasting blood sugar and improved glucose response in these mice, compared to the control. Furthermore, implantation of insulin pellets into the mice not only reduced fasting blood sugar and improved glucose response, but also significantly reduced the incidence of development of PDAC, which mimicked the effect of swimming. Taken together, our study suggests that sports-induced blood sugar utilization may prevent development of PDAC.

13 Retraction Randomized Trial Comparing the Flexible 19G and 25G Needles for Endoscopic Ultrasound-Guided Fine Needle Aspiration of Solid Pancreatic Mass Lesions. 2015

Ramesh, Jayapal / Bang, Ji Young / Hebert-Magee, Shantel / Trevino, Jessica / Eltoum, Isam / Frost, Andra / Hasan, Muhammad K / Logue, Amy / Hawes, Robert / Varadarajulu, Shyam. ·From the *Division of Gastroenterology and Hepatology and †Department of Pathology, University of Alabama at Birmingham, Birmingham, AL; and ‡Center for Interventional Endoscopy, Florida Hospital, Orlando, FL. ·Pancreas · Pubmed #25232713.

ABSTRACT: OBJECTIVES: Although a large gauge needle can procure more tissue at endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), its advantage over smaller needles is unclear. This study compared flexible 19G and 25G needles for EUS-FNA of solid pancreatic masses. METHODS: This was a randomized trial of patients undergoing EUS-FNA of pancreatic masses using flexible 19G or 25G needle. Main outcome measure was to compare median number of passes for on-site diagnosis. Secondary measures were to compare specimen bloodiness, complications, technical failures, and histological core tissue procurement. RESULTS: One hundred patients were randomized to EUS-FNA using flexible 19G or 25G needle. Median of 1 pass was required to achieve on-site diagnosis of 96% and 92% (P = 0.68) in 19G and 25G cohorts. There was no significant difference in technical failure (0% vs 2%, P = 0.99) or adverse events (2% vs 0%, P = 0.99) between 19G and 25G cohorts. Although histological core tissue procurement was significantly better with flexible 19G needle (88% vs 44%, P < 0.001), specimens were bloodier (severe bloodiness, 36% vs 4%; P < 0.001). CONCLUSIONS: As there is no significant difference in the performance of flexible 19G and 25G needles, needle choice for sampling pancreatic masses should be based on endoscopist preference and need for histology.

14 Retraction A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients. 2014

Yao, Jun / Wang, Jian-yao / Liu, Yi / Wang, Bin / Li, Ying-xue / Zhang, Ru / Wang, Li-sheng / Liu, Lei. ·Department of Gastroenterology, Shenzhen Municipal People's Hospital, Jinan University of Medical Sciences, 1017 East Gate Road, Shenzhen, 518020, Guangdong Province, China. ·Med Oncol · Pubmed #25395378.

ABSTRACT: Everolimus, an oral inhibitor of mammalian target of mTOR, has been recently shown to have antitumor effect in a phase III, double-blind, randomized trial (RADIANT-3) of 410 patients with advanced pancreatic neuroendocrine tumors (PNETs). The purpose of this study was to investigate the specific efficacy and safety of everolimus in the Chinese patient with PNETs. In this randomized phase II study, the analysis on Chinese patients was performed comparing efficacy and safety between everolimus 10 mg/day orally (n = 44) and matching placebo (n = 35). The primary endpoint was progression-free survival (PFS). Adverse events were also examined. The median PFS was 15.47 months with everolimus [95% confidence interval (CI) 10.52-26.37], as compared to 4.29 months with placebo (95% CI 2.22-10.75), representing a 72% reduction in the risk of progression or death (hazard ratio 0.27; 95% CI 0.13-0.59; P < 0.001). Drug-associated adverse events (AEs) were mostly grade 1 or 2, observed in all 44 (100%) patients receiving everolimus and in 29 (83%) patients receiving placebo. The most common AEs (grade 1-4) associated with everolimus were rash (n = 38; 86%), stomatitis (n = 30; 68%), infections (n = 33; 75%), epistaxis (n = 32; 73%), pneumonitis (n = 27; 61%) and anemia (n = 22; 50%). Everolimus when compared with placebo is effectively in improving PFS in Chinese patients with PNETs.

15 Retraction Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. 2014

Lai, I-Lu / Chou, Chih-Chien / Lai, Po-Ting / Fang, Chun-Sheng / Shirley, Lawrence A / Yan, Ribai / Mo, Xiaokui / Bloomston, Mark / Kulp, Samuel K / Bekaii-Saab, Tanios / Chen, Ching-Shih. ·Division of Medicinal Chemistry, College of Pharmacy. · Division of Surgical Oncology, Department of Surgery. · Center for Biostatistics and. · Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, OH 43210, USA and. · Division of Medicinal Chemistry, College of Pharmacy, Institute of Basic Medical Sciences, National Cheng-Kung University, Tainan 704, Taiwan chen.844@osu.edu. ·Carcinogenesis · Pubmed #24879635.

ABSTRACT: Gemcitabine resistance remains a significant clinical challenge. Here, we used a novel glucose transporter (Glut) inhibitor, CG-5, as a proof-of-concept compound to investigate the therapeutic utility of targeting the Warburg effect to overcome gemcitabine resistance in pancreatic cancer. The effects of gemcitabine and/or CG-5 on viability, survival, glucose uptake and DNA damage were evaluated in gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cell lines. Mechanistic studies were conducted to determine the molecular basis of gemcitabine resistance and the mechanism of CG-5-induced sensitization to gemcitabine. The effects of CG-5 on gemcitabine sensitivity were investigated in a xenograft tumor model of gemcitabine-resistant pancreatic cancer. In contrast to gemcitabine-sensitive pancreatic cancer cells, the resistant Panc-1 and Panc-1(GemR) cells responded to gemcitabine by increasing the expression of ribonucleotide reductase M2 catalytic subunit (RRM2) through E2F1-mediated transcriptional activation. Acting as a pan-Glut inhibitor, CG-5 abrogated this gemcitabine-induced upregulation of RRM2 through decreased E2F1 expression, thereby enhancing gemcitabine-induced DNA damage and inhibition of cell survival. This CG-5-induced inhibition of E2F1 expression was mediated by the induction of a previously unreported E2F1-targeted microRNA, miR-520f. The addition of oral CG-5 to gemcitabine therapy caused greater suppression of Panc-1(GemR) xenograft tumor growth in vivo than either drug alone. Glut inhibition may be an effective strategy to enhance gemcitabine activity for the treatment of pancreatic cancer.

16 Retraction Uncovering the pathogenesis and identifying novel targets of pancreatic cancer using bioinformatics approach. 2014

Zhao, Li-Li / Zhang, Tong / Zhuang, Li-Wei / Yan, Bing-Zhu / Wang, Rui-Feng / Liu, Bing-Rong. ·Department of Gastroenterology, The Fourth Affiliated Hospital of Harbin Medical University, No. 37 Yiyuan Street, Nangang District, Harbin, 150001, Heilongjiang, China. ·Mol Biol Rep · Pubmed #24728565.

ABSTRACT: Pancreatic cancer is a uniformly lethal disease that can be difficult to diagnose at its early stage. Thus, our present study aimed to explore the underlying mechanism and identify new targets for this disease. The data GSE16515, including 36 tumor and 16 normal samples were available from Gene Expression Omnibus. Differentially expressed genes (DEGs) were screened out using Robust Multichip Averaging and LIMMA package. Moreover, gene ontology and pathway enrichment analyses were performed to DEGs. Followed with protein-protein interaction (PPI) network construction by STRING and Cytoscape, module analysis was conducted using ClusterONE. Finally, based on PubMed, text mining about these DEGs was carried out. Total 274 up-regulated and 93 down-regulated genes were identified as the common DEGs and these genes were discovered significantly enriched in cell adhesion and extracellular region terms, as well as ECM-receptor interaction pathway. In addition, five modules were screened out from the up-regulated PPI network with none in down-regulated network. Finally, the up-regulated genes, including MIA, MET and CEACAMS, and down-regulated genes, such as FGF, INS and LAPP, had the most references in text mining analysis. Our findings demonstrate that the up- and down-regulated genes play important roles in pancreatic cancer development and might be new targets for the therapy.

17 Retraction Diagnostic performance of serum macrophage inhibitory cytokine-1 in pancreatic cancer: a meta-analysis and meta-regression analysis. 2014

Chen, Yan-Zhi / Liu, Dan / Zhao, Yu-Xia / Wang, He-Tong / Gao, Ya / Chen, Ying. ·Department of Radiotherapy, The Fourth Affiliated Hospital of China Medical University , Shenyang, People's Republic of China . ·DNA Cell Biol · Pubmed #24592997.

ABSTRACT: Many existing studies have demonstrated that the macrophage inhibitory cytokine-1 (MIC-1) might be a powerful diagnostic biomarker in patients with pancreatic cancer; but individually published results are inconclusive. This meta-analysis aimed to derive a more precise estimation of the diagnostic performance of serum MIC-1 in pancreatic cancer. We searched CISCOM, CINAHL, Web of Science, PubMed, Google Scholar, EBSCO, Cochrane Library, China BioMedicine (CBM), and China National Knowledge Infrastructure (CNKI) databases from their inception through August 1st, 2013. Meta-analysis was performed using Meta-Disc version 1.4 and STATA version 12.0 software. Crude standardized mean difference (SMD) and their 95% confidence intervals (CI) were estimated. Data from selected studies were pooled to yield summary sensitivity, specificity, positive and negative likelihood ratio (LR), diagnostic odds ratio (DOR), and receiver operating characteristic (SROC) curve. Ten case-control studies were included in this meta-analysis with a total of 1235 pancreatic cancer patients and 730 healthy subjects. Our meta-analysis results revealed that serum MIC-1 levels in pancreatic patients were higher than those of healthy subjects (SMD=1.38, 95% CI=1.15-1.62, p<0.001). The area under the SROC curve was 0.92 (SE=0.020); the pooled sensitivity was 0.79 (95% CI=0.77-0.82); and the pooled specificity was 0.86 (95% CI=0.84-0.88). The pooled positive LR was 6.20 (95% CI=1.24-30.91); the pooled DOR was 35.73 (95% CI=18.52-68.93). In conclusion, the present meta-analysis suggests that serum MIC-1 may be a useful diagnostic biomarker with high sensitivity and specificity for identifying pancreatic cancer.

18 Retraction Candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method. 2014

Lin, Yan / Jin, Yu / Lin, Lian-Jie / Cao, Yong / Zhang, Ying / Chen, Shao-Fu / Zheng, Chang-Qing. ·Department of Gastroenterology, Shengjing Hospital, China Medical University, Shenyang 110001, Liaoning Province, China. · Department of Gastroenterology, Shengjing Hospital, China Medical University, Shenyang 110001, Liaoning Province, China. Electronic address: changqingzheng2@hotmail.com. ·Gene · Pubmed #24561286.

ABSTRACT: AIM: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death worldwide. This study aims to explore the molecular mechanism of PDAC and identify biologically active small molecules capable of targeting the sub-pathways which were dysregulated in the development of PDAC. METHODS: The gene expression profile of GSE28735 microarray data (including 45 matching pairs of pancreatic tumor and adjacent non-tumor tissues) was downloaded from GEO (Gene Expression Omnibus) database. Differentially expressed genes (DEGs) between pancreatic tumor tissues and non-tumor tissues were identified, and then the sub-pathway enrichment analysis was performed. Moreover, an approach based on targeting sub-pathways was used to reveal potential agents for PDAC. RESULTS: A total of 5315 DEGs were identified between pancreatic tumor tissues and non-tumor tissues with a false discovery rate of 0.01. Genes of collagen family and integrin receptor family which were involved in pathways of focal adhesion and ECM-receptor interaction respectively were differentially expressed in the pancreatic tumor tissue. Besides, a total of 85 small molecules including fludrocortisone, latamoxef and metronidazole were revealed by bioinformatics analysis. CONCLUSION: This study proposed the use of an approach based on targeting sub-pathways to identify potential agents for PDAC. The sub-pathways and small molecules discovered in this study were not only related to PDAC but also play a role in perturbing the development of PDAC.

19 Retraction Construction of pancreatic cancer double-factor regulatory network based on chip data on the transcriptional level. 2014

Zhao, Li-Li / Zhang, Tong / Liu, Bing-Rong / Liu, Tie-Fu / Tao, Na / Zhuang, Li-Wei. ·Department of Gastroenterology, The Fourth Affiliated Hospital of Harbin Medical University, No. 37 Yiyuan Street, Nangang District, Harbin, 150001, Heilongjiang, China. ·Mol Biol Rep · Pubmed #24469724.

ABSTRACT: Transcription factor (TF) and microRNA (miRNA) have been discovered playing crucial roles in cancer development. However, the effect of TFs and miRNAs in pancreatic cancer pathogenesis remains vague. We attempted to reveal the possible mechanism of pancreatic cancer based on transcription level. Using GSE16515 datasets downloaded from gene expression omnibus database, we first identified the differentially expressed genes (DEGs) in pancreatic cancer by the limma package in R. Then the DEGs were mapped into DAVID to conduct the kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis. TFs and miRNAs that DEGs significantly enriched were identified by Fisher's test, and then the pancreatic cancer double-factor regulatory network was constructed. In our study, total 1117 DEGs were identified and they significantly enriched in 4 KEGG pathways. A double-factor regulatory network was established, including 29 DEGs, 24 TFs, 25 miRNAs. In the network, LAMC2, BRIP1 and miR155 were identified which may be involved in pancreatic cancer development. In conclusion, the double-factor regulatory network was found to play an important role in pancreatic cancer progression and our results shed new light on the molecular mechanism of pancreatic cancer.

20 Retraction Lack of association of XRCC1 rs1799782 genetic polymorphism with risk of pancreatic cancer: a meta-analysis. 2014

He, Gengsheng / Chen, Guodong / Chen, Wenqi / Zhang, Wei / Cao, Jinmin / Ye, Qifa. ·Center of Transplant Surgery, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, People's Republic of China. ·Tumour Biol · Pubmed #24435745.

ABSTRACT: CT/CC: OR = 1.07, 95% CI 0.73-1.55, P = 0.743; T vs. C: OR = 1.31, 95% CI 0.93-1.86, P = 0.125). In the subgroup analysis based on ethnicity, there was no statistically significant association between XRCC1 rs1799782 genetic polymorphism and pancreatic cancer risk in Asians/Caucasians under all genetic models (all P values > 0.05). No publication bias was detected in this study. Our meta-analysis suggests that the XRCC1 rs1799782 genetic polymorphism is not significantly associated with pancreatic cancer risk. Considering the limited sample size and ethnicity enrolled in this meta-analysis, further larger scaled studies are needed to provide a more precise estimation on the association.

21 Retraction Association between single-nucleotide polymorphisms of OGG1 gene and pancreatic cancer risk in Chinese Han population. 2014

Chen, Hongxu / Zhou, Bo / Lan, Xiang / Wei, Dong / Yuan, Tao / Chen, Ping. ·Department of Hepatobiliary Surgery, Daping Hospital, The Third Military Medical University, No. 10 Changjiangzhilu Daping, Chongqing, 400042, People's Republic of China. ·Tumour Biol · Pubmed #23999824.

ABSTRACT: The purpose of this study was to test the association between single-nucleotide polymorphisms (SNPs) of 8-oxoguanine DNA glycosylase (OGG1) gene and susceptibility to pancreatic cancer (PC). A total of 347 PC patients and 364 healthy subjects were enrolled in this case-control study. The c.269C>A genetic variant was investigated using the created restriction site-polymerase chain reaction method. The c.627T>C genetic variant was identified by the polymerase chain reaction-restriction fragment length polymorphism method. Our data indicated that the alleles and genotypes frequencies of these two SNPs were statistically different in PC cases and controls. As for c.269C>A, the AA genotype was statistically associated with decreased PC susceptibility compared to CC wild genotype (odds ratio (OR) = 0.44, 95% confidence interval (CI) 0.27-0.73, P = 0.001). As for c.627T>C, statistically significant decreased PC susceptibility was detected in CC genotype compared to TT wild genotype (OR = 0.57, 95% CI 0.35-0.94, P = 0.028). The allele A of c.269C>A and allele C of c.627T>C might be associated with a protection from PC (for c.269C>A, A versus (vs.) C, OR = 0.69, 95% CI 0.55-0.86, P < 0.001; for c.627T>C, C vs. T, OR = 0.72, 95% CI 0.58-0.91, P = 0.005). Results from this study indicate that the c.269C>A and c.627T>C SNPs of OGG1 gene are associated with PC susceptibility in Chinese Han ethnicity.

22 Retraction Association of XRCC1 gene single nucleotide polymorphisms and susceptibility to pancreatic cancer in Chinese. 2014

Chen, Hongxu / Tang, Chun / Liu, Menggang / Zhou, Bo / Kuang, Yi / Yuan, Tao / Chen, Ping. ·Department of Hepatobiliary Surgery, Daping Hospital, The Third Military Medical University, No. 10 Changjiangzhilu Daping, Chongqing, 400042, People's Republic of China. ·Tumour Biol · Pubmed #23893380.

ABSTRACT: The human X-ray repair cross-complementing group 1 gene (XRCC1) is an important candidate gene for affecting pancreatic cancer (PC) risk. The objective of this study was to detect whether the c.1471G > A and c.1686C > G polymorphisms of XRCC1 gene influence PC risk. The association of XRCC1 genetic variants with PC risk was analyzed in 328 PC patients and 350 controls by the polymerase chain reaction-restriction fragment length polymorphism and created restriction site-polymerase chain reaction method. Our data suggested that the genotypes and alleles from these two genetic variants were statistically associated with PC risk. For c.1471G > A, the AA genotype was associated with the decreased risk of developing PC compared to GG wild genotype (odds ratio (OR) = 0.43, 95% confidence intervals (CI) 0.26-0.70, chi-squared (χ(2)) = 11.91, P = 0.001). For c.1686C > G, the risk of PC was significantly lower for GG genotype in comparing to CC wild genotype (OR = 0.48, 95% CI 0.29-0.81, χ(2) = 7.98, P = 0.005). The A allele of c.1471G > A and G allele of c.1686C > G genetic variants could contribute to decrease the risk of PC (for c.1471G > A: A vs G, OR = 0.65, 95% CI 0.52-0.82, χ(2) = 13.71, P < 0.001, for c.1686C > G: G vs C, OR = 0.70, 95% CI 0.55-0.88, χ(2) = 9.42, P = 0.002). Our findings indicate that the c.1471G > A and c.1686C > G polymorphisms of XRCC1 gene are associated with PC risk in Chinese population.

23 Retraction Surgical selection for late pancreatic head carcinoma without gastric outlet obstruction. 2013

Zhang, Shu-Hua / Wang, Juan / Yang, Chong / Wang, Bo / Wu, He-Shui / Wang, Chun-You. ·Pancreatic Disease Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. · Department of Internal Medicine, Wuhan Sixth Hospital, Wuhan, 430022, China. · Pancreatic Disease Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. fyangzy@gmail.com. · Pancreatic Disease Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. heshuiwu@163.com. ·J Huazhong Univ Sci Technolog Med Sci · Pubmed #24337850.

ABSTRACT: The effects of different surgical procedures for late pancreatic head carcinoma without gastric outlet obstruction were explored in order to provide theoretical basis to select a suitable operation for these patients. The clinical data of 441 cases of late pancreatic head carcinoma without gastric outlet obstruction were retrospectively analyzed. All patients were divided into 4 groups based on different surgical procedures: group A (101 cases) subjected to Roux-en-Y cholecystojejunostomy; group B (133 cases) undergoing Roux-en-Y choledochojejunostomy; group C (83 cases) given Roux-en-Y cholecystojejunostomy combined with gastrojejunostomy; group D (124 cases) receiving Roux-en-Y choledochojejunostomy combined with gastrojejunostomy. Therapeutic efficacy in each group was evaluated comparatively. Both groups B and D had a lower rate of postoperative obstructive jaundice than groups A and C separately (P<0.05 for all). The data of mean life span showed that both groups B and D had a lower survival rate than groups A and C separately (P<0.05 for all). The incidence of postoperative gastric outlet obstruction in groups A and B was higher than that in groups C and D separately (P<0.05 for all). The gastrojejunostomy had no impacts on the mean life span, and there was no statistically significant difference in complications, average hospital stay (days) and median survival among four groups (P>0.05). For the late pancreatic head carcinoma without gastric outlet obstruction, Roux-en-Y choledochojejunostomy is effective for the reduction of icteric index and the incidence of recurrent jaundice, also offers an opportunity for prolonged survival. Combined use of prophylactic Roux-en-Y gastrojejunostomy during surgical biliary drainage is safe for advanced pancreatic carcinoma with obstructive jaundice, which can decrease the incidence of postoperative gastric outlet obstruction, and has important implications for improving outcomes.

24 Retraction Meta-analysis of the efficacy of pancreatoduodenectomy with extended lymphadenectomy in the treatment of pancreatic cancer. 2013

Xu, Xinbao / Zhang, Hui / Zhou, Ping / Chen, Lei. ·Department of Hepatobiliary Surgery, Airforce General Hospital of Chinese People's Liberation Army, Beijing 100142, China. xu_xinbao@sohu.com. ·World J Surg Oncol · Pubmed #24321394.

ABSTRACT: BACKGROUND: The purpose of this meta-analysis is to compare the efficacy of pancreatoduodenectomy (PD) with extended lymphadenectomy (PD/ELND) versus standard PD in the treatment of pancreatic cancer, with the hope of providing evidence for clinical practice. METHODS: The retrieval of relevant literature published before September 2012 was carried out on PubMed, Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) by computer. Information was extracted according to Cochrane systematic review methods, and analyzed using software Stata 11.0. RESULTS: Five prospective randomized controlled trials (RCTs) were included in this meta-analysis of 555 cases (278 in the PD/ELND group and 277 in the standard PD group). The PD/ELND group showed a significantly lower 3-year survival rate (relative risk (RR) = 1.46, 95% confidence interval (CI) 1.03 to approximately 2.06, P = 0.034), prolonged operative time (weighted mean difference WMD = -1.03, 95% CI -1.96 to approximately -0.10, P = 0.029) and higher incidence of postoperative complications (RR = 0.56, 95% CI 0.42 to approximately 0.77, P = 0.000) by comparing with standard PD group. Besides, no significant difference was observed in the 1-year survival rate (RR = 0.87, 95% CI 0.60 to approximately 1.25, P = 0.69), 5-year survival rate (RR = 1.04, 95% CI 0.68 to approximately 1.58, P = 0.854), postoperative mortality (RR = 1.14, 95% CI 0.43 to approximately 3.00, P = 0.789), length of stay (WMD = -0.32, 95% CI -2.57 to approximately 1.94 , P = 0.784) and the amount of blood transfusions (WMD = -0.14, 95% CI -0.36 to approximately 0.08, P = 0.213). CONCLUSIONS: PD/ELND does not have an advantage over standard PD in the survival rate for patients with pancreatic cancer, but does increase operative time and incidences of postoperative complications.

25 Retraction The hypoxia-inducible factor-1 regulates the microRNA185 expression through binding to hypoxia response elements sequence 2. 2013

Song, Zhenguo / Ren, He / Gao, Song / Zhao, Tiansuo / Wang, Xiuchao / Zhang, Shengjie / Zhao, Xiao / Jia, Lingling / Sun, Junwei / Hao, Jihui. ·Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. ·Med Oncol · Pubmed #24198204.

ABSTRACT: This study aimed to investigate the interaction and regulatory mechanism of microRNA185 (miR185) and hypoxia-inducible factor-1 (HIF-1) in pancreatic cancer. The significance of miR185 on the clinicopathologic characteristics and prognosis was further explored. qRT-PCR and immunohistochemistry examined miR185 and HIF-1 expression of tumor tissues. Western blot analyzed HIF-1 protein expression. We regulated HIF-1 via transfection to observe the impact of HIF-1 on miR185 expression. ChIP sequencing and dual luciferase identified binding sites of HIF-1 and miR185. MiR185 expression was significantly higher in pancreatic tumors. MiR185 closely associated with tumor size, pTNM stage, lymph node, and perneural invasion. After hypoxic culture, both HIF-1 and miR185 expression of MiaPaCa2 and AsPc1 cells increased significantly. Up- or down-regulating HIF-1 expression via transfection leads to synchronous alteration of miR185. In ChIP sequencing, only the HRE2 (-938 bp) was significantly brighter under hypoxia among four hypoxia response elements' (HREs) sequence of miR185 promoter. After pGL3-miR185 and HIF-1 over-expressing plasmids co-transfect the MiaPaCa2 cells, its relative expression of bioluminescence increased. MiR185 expression was significantly higher in tumor tissues and closely associated with the clinical features of pancreatic cancer. Expression of HIF-1 in pancreatic cancer cells increased in hypoxia. HIF-1 may bind to HRE2 of miR185 and initiate its transcription.

Next